Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Regeneron Pharmaceuticals Inc. Stock

Price
Target price
€840.00

€840.00

-0.900%
-7.6
-0.900%
€954.29

€954.29

 
Buy 32 Sell 1
Buy 32
Sell 1
08:00 / Tradegate WKN: 881535 / Symbol: REGN / Name: Regeneron / Stock / Biotechnology & Medical Research / Large Cap /
Latest predictions
20.04.24
0.52%
buy
14.04.24
-1.03%
buy
13.04.24
-1.03%
buy
€676.58
12.04.24
-0.42%
sell
€1,092.5
09.04.24
-2.71%
buy
€1,049.8
03.04.24
-4.25%
buy
Show more
Best running prediction
€828.28
04.08.23
22.40%
buy
Your prediction
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Wizard

Regeneron Pharmaceuticals Inc. Stock

The price for the Regeneron Pharmaceuticals Inc. stock decreased slightly today. Compared to yesterday there is a change of -€7.600 (-0.900%).
With 32 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 954 € shows a slightly positive potential of 13.57% compared to the current price of 840.0 € for Regeneron Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Regeneron Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years

Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Regeneron Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Regeneron Pharmaceuticals Inc. -0.900% 0.689% -5.349% 16.349% 6.282% 110.010% 175.867%
Exact Sciences -0.290% -2.512% 2.180% -4.498% -14.490% -47.064% -27.833%
Incyte Corp. -1.520% -4.057% -8.498% -28.933% -14.981% -31.787% -28.480%
Amgen Inc. 0.590% 2.179% 0.000% 15.135% -1.919% 20.339% 59.471%

Comments

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for REGN provided by MarketBeat
Show more

StockNews.com 
0
Report Share
20.04.24 Buy 0.52%

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for REGN provided by MarketBeat
Show more

StockNews.com 
0
Report Share
13.04.24 Buy -1.03%
Prediction Sell
Perf. (%) -0.42%
Target price 676.584
Change
Ends at 12.04.25

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Bank of America Co. from $710.00 to $720.00. They now have an "underperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Bank of America Co. 
0
Report Share
12.04.24
Show more
Not a member yet? Sign up for free!

News

Should You Sell This Stock Following a Regulatory Roadblock?: https://g.foolcdn.com/editorial/images/770862/physician-talking-to-patient.jpg
Should You Sell This Stock Following a Regulatory Roadblock?

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its

TheMotleyFool 
0 05.04.24
2 Biotech Stocks to Buy Hand Over Fist in March: https://g.foolcdn.com/editorial/images/767744/doctor-and-patient-in-a-hospital-room.jpg
2 Biotech Stocks to Buy Hand Over Fist in March

Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry

TheMotleyFool 
0 08.03.24
2 No-Brainer Biotech Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/765481/doctor-and-patient-talking.jpg
2 No-Brainer Biotech Stocks to Buy Right Now

Those looking to invest in stocks can sometimes seem spoiled for choices. There are all kinds of businesses in the equity markets that seem intriguing. However, upon closer inspection, many of these

TheMotleyFool 
0 21.02.24